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ncidence and Predictors of Very Late
>4 Years) Major Cardiac Adverse Events
n the DESIRE (Drug-Eluting Stents in the
eal World)-Late Registry
. Ribamar Costa, JR, MD, Amanda Sousa, MD, PHD, Adriana C. Moreira, MD,
icardo A. Costa, MD, Manuel Cano, MD, Galo Maldonado, MD, Cantı´dio Campos, BS,
ariana Carballo, BS, Ricardo Pavanello, MD, J. Eduardo Sousa, MD
ão Paulo, Brazil
bjectives Our aim was to access the incidence of late major adverse cardiac events (MACE) and
tent thrombosis (ST) in nonselected, complex patients followed for a period 4 years.
ackground Despite the efﬁcacy of drug-eluting stents (DES) in reducing repeated target lesion
evascularization, concerns regarding the occurrence of late and very late ST have partially obscured
he beneﬁts of this novel technology.
ethods All consecutive patients treated solely with DES between May 2002 and January 2005
ere enrolled into this prospective, nonrandomized, single-center registry. The primary end point
as long-term occurrence of MACE up to 7 years. Independent predictors of MACE, cardiac death,
arget lesion revascularization, and ST were obtained by a multivariate Cox proportional hazards re-
ression model.
esults A total of 1,010 patients were enrolled. Most of them were men (77%) with a mean age of
3.7 years. Stent/patient rate was 1.4. Patients were kept in dual antiplatelet therapy for 3 and 6
onths after Cypher (Cordis, Johnson & Johnson, Miami Lakes, Florida) and Taxus (Boston Scientiﬁc
orp., Natick, Massachusetts) stent implantation, respectively. Follow-up was obtained in 98.2% of
he cohort (median 5.01 years). Survival free of MACE and cumulative incidence of deﬁnite/probable
T were 84.6% and 1.7%, respectively. Independent predictors of ST were percutaneous coronary
ntervention in the setting of acute myocardial infarction, DES overlapping, treatment of multivessel
isease, presence of moderate-to-severe calciﬁcation at lesion site, and in-stent residual stenosis.
onclusions The deployment of DES in complex, real-world patients resulted in a low rate of very
ong-term MACE and ST. However, ST still occurs very long after the index procedure. (J Am Coll
ardiol Intv 2010;3:12–8) © 2010 by the American College of Cardiology Foundation
rom the Instituto de Ensino e Pesquisa, Hospital do Coração, São Paulo, Brazil.anuscript received June 16, 2009; revised manuscript received September 4, 2009, accepted October 15, 2009.
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13espite the unequivocal efficacy of first-generation drug-
luting stent (DES) (Cypher, Cordis, Johnson & Johnson,
iami Lakes, Florida, and Taxus, Boston Scientific Corp.,
atick, Massachusetts) in reducing the need for repeat
esion revascularization, the relatively recent introduction of
his novel technology in the clinical scenario (10 years)
recludes definite assessment of very long-term mainte-
ance of their efficacy and safety profile.
See page 19
Initial data suggest a steady annual increment in the rates
f cardiac death as well as the occurrence of late and very
ate stent thrombosis and restenosis (after the first year of
he index procedure) (1–4). However, very long-term
ollow-up data (4 years) in large, nonselected populations
re still limited. We sought to assess the latest clinical
ollow-up of a consecutive “real-world” series of patients
reated with first-generation DES as well as to establish the
ain predictors of adverse cardiac events among these
atients.
ethods
tudy design and population. Between May 2002 and Jan-
ary 2005, all patients treated in a single, private center
Hospital do Coração, São Paulo, Brazil) with 1 DES
ere included in the nonrandomized, DESIRE (Drug-
luting Stents In REal world)-Late registry. Clinical inclu-
ion criteria were “all comers” for routine or emergency
ercutaneous coronary intervention (PCI) 18 years of age.
ngiographic inclusion criteria were the presence of at least
documented stenosis 50% (by visual estimation) in a
ative coronary vessel or graft (arterial or venous) suitable
or PCI with DES implantation. There were no protocol
re-specified limitations concerning the number of target
esions and/or target vessels that could to be treated with
ES. Figure 1 shows the rate of use of bare-metal stents
BMS) and DES in our institution during the enrollment
eriod. Since this study is based on clinical end points,
atients receiving both DES and BMS were excluded from
his analysis.
The study was approved by the institutional ethics com-
ittee. Written informed consent was obtained from all
atients before the procedure. The institution and the
articipants did not receive any kind of financial support to
evelop this research.
tenting procedure. All interventions were performed ac-
ording to the current standard guidelines, and the final
rocedure strategy was entirely left to operators’ discretion.
wo different DES were available at that time: 1) sirolimus-
luting stents (Cypher, Cordis, Johnson & Johnson) in
iameters ranging from 2.25 to 3.5 mm and lengths from 8
o 33 mm; and 2) paclitaxel-eluting stents (Taxus, Boston lcientific Corp.) in diameters ranging from 2.25 to 4.0 mm
nd lengths from 8 to 32 mm. The type of stent to be
eployed as well as the strategy to pre- and/or post-dilatate
as left to the operator’s discretion. Multiple stenting
rocedure with the DES was allowed. Dual antiplatelet
herapy including a loading dose of aspirin (200 to 325 mg)
nd thienopyridines (ticlopidine 250 mg twice a day or
lopidogrel 300 mg) was started at least 24 h before elective
rocedures; otherwise a loading dose of 600 mg of clopi-
ogrel was given immediately before the intervention. Post-
rocedural aspirin was continued indefinitely, and thienopy-
idine was maintained for only 3 months after Cypher and
months after Taxus deployment. During the procedure,
ntravenous heparin (70 to 100 IU/kg) was administered
fter sheath insertion to maintain an activated clotting time
250 s. Use of additional medications during the proce-
ure, including glycoprotein IIb/
IIa inhibitors, was left to the
perator’s discretion. A 12-lead
lectrocardiogram was obtained
efore the procedure, immedi-
tely afterward, and 24 h later.
lood sample laboratory analysis
ncluded creatine kinase cardiac
nzymes (CK and CK-MB) be-
ore the procedure (24 h) and
2 to 18 h after treatment.
ngiographic analysis. After in-
racoronary nitrate administra-
ion (100 to 200 g), serial cor-
nary angiography was obtained
t baseline and post-procedure.
ffline quantitative coronary an-
iography (QCA) analysis was
erformed using the semiauto-
atic edge contour-detection
omputer analysis system CMS-
FT version 5.1 (Medis, Lei-
en, the Netherlands). The minimum lumen diameter
MLD) and the mean reference diameter (RD), obtained
rom averaging 5 mm “nondiseased” segments proximal and
istal to the target lesion location(s), were used to calculate
he diameter stenosis (DS): DS  (1 MLD/RD)  100.
cute gain was the change in MLD from baseline to final
ost-stent implantation angiogram.
All cineangiograms images were analyzed at the Hospital
o Coração Angiographic Core Laboratory (São Paulo,
razil) by experienced senior operators blinded to proce-
ural data.
nd points, deﬁnitions, and clinical follow-up. The study’s
rimary objective was the occurrence of major adverse
ardiac events (MACE) and stent thrombosis at the very
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CI  confidence interval
CK  creatine kinase
DES  drug-eluting stent(s)
DS  diameter stenosis
HR  hazard ratio
MACE  major adverse
cardiac events
MLD  minimum lumen
diameter
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
RD  reference diameter
TVR  target vessel
revascularizationong-term (4 years) clinical evolution.
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14MACE was defined as cardiac death, nonfatal myocardial
nfarction, and target vessel revascularization (TVR). TVR
as only based on the presence of symptoms and/or signs of
schemia. All deaths were considered to be cardiac unless a
oncardiac origin could be clearly established by clinical
nd/or pathological study. The diagnosis of myocardial
nfarction was based on either the development of new
athological Q waves in 2 contiguous electrocardiogram
eads, and/or elevation of CK-MB isoenzyme 3 times the
pper normal limit post-procedure during index hospital-
zation, or cardiac enzyme elevation 2 times the upper
ormal limit thereafter.
Stent thrombosis was classified as definite, probable, and
ossible according to definitions proposed by the Academic
esearch Consortium (5), and was stratified as acute
24 h), subacute (24 h to 30 days), and late (1 to 12
onths) and very late (12 months).
Angiographic success was defined as attainment of20%
esidual stenosis by QCA in the treated segment post-DES
reatment. Procedural success was defined as angiographic
uccess plus absence of MACE during hospitalization.
uring the enrollment period, detailed demographic, clin-
cal, angiographic, and procedural information, including
omplications, were gathered for each patient. Clinical
ollow-ups, by office appointment or phone call, were
cheduled at 1, 6, and 12 months after stent implantation,
nd then annually up to 7 years of the baseline procedure on
he basis of information entered on case report forms at the
ime of the office visit/telephone contact. At the time of the
ollow-up, data were collected pertaining to current clinical
tatus, concomitant drug-therapy (with special emphasis to
Figure 1. BMS and DES Usage in Our Center
Rates of bare-metal stent (BMS) and drug-eluting stent (DES) deployment
in our institution during the enrollment phase of the DESIRE (Drug-Eluting
Stents In the REal world)-Late study (May 2002 to January 2005).he antiplatelet regimen), and interim occurrence of the vre-defined adverse events. All phone follow-up data were
ollected by the same person especially trained for this task
nd blinded to the procedure results. Individual patient data
as coded to prevent the identification of study participants.
outine angiographic follow-up was not part of the study
rotocol. Therefore, all reinterventions were clinically
ischemia)-driven. Adverse events were adjudicated by an
ndependent committee of 3 cardiologists not involved in
he procedures.
tatistical analysis. Data are presented as mean  1 SD or
requencies. Categorical variables were compared with the
hi-square test. When the assumptions were broken, Fisher
xact test was used. For continuous variables comparison, t
est was used. Event-free survivals for MACE, TVR, and
tent thrombosis were demonstrated by Kaplan-Meier
urves.
A multivariate Cox proportional hazards regression was
sed. Fully adjusted MACE, TVR, and stent thrombosis
odels were fit to include demographic characteristics,
linical presentation variables, periprocedural medications,
nd procedural characteristics as well as lesion complexity.
ovariates were selected by forward stepwise methods and
hose considered biologically relevant despite their statistical
ignificance. A value of p 0.05 was considered significant.
tatistical analysis was performed using SPSS version 11.0
SPSS Inc., Chicago, Illinois).
esults
total of 1,010 patients (1,294 lesions) were enrolled. Most
f them were men (77%), and the mean age was 63.7 11.6
ears. Diabetes mellitus was observed in 27.1% of this
opulation, and 54.2% of the patients had been previously
ubmitted to a revascularization procedure either by PCI
25.5%) or coronary artery bypass grafting (28.7%). Acute
oronary syndrome was the initial presentation in 37.6% of
he cases (12.2% of ST-segment elevation myocardial in-
arction). Table 1 contains detailed baseline characteristics
f this cohort.
Table 2 details the main baseline lesion characteristics.
ost patients had double (30.4%) or triple (22.9%) vessel
isease. Left anterior descending artery was the most
requently treated native coronary (40.4%). Of note, 6.3% of
he target lesions were located in venous or arterial grafts.
lso relevant, in 28.5% of the lesions, moderate-to-severe
alcification could be identified by angiography.
Procedural and QCA information are displayed in Table 3.
verall, there were 1,414 DES implanted (1.4 stents per
atient). Pre-dilation was performed in less than one-half of
he population (41%), and 38.1% of the treated patients
equired more than 1 DES. Cypher was the DES used in
1% of the cases. Glycoprotein IIb/IIIa inhibitors were used
n only 2.7% of cases. Mean lesion length and reference
essel diameter were 16.4  8.2 mm and 2.76  0.47 mm,
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15espectively. Mean acute gain was estimated at 1.81  0.9
m with final in-stent minimal lumen diameter of 2.85 
.0 mm and residual stenosis of 4.7  3.6%. Mean nominal
tent length was 19.2 5.8 mm, and the stent/lesion length
atio was 1.2. No case of intraprocedure stent thrombosis
as verified in this series. Angiographic and procedure
uccess were achieved in 99% and 98.3% of the cases.
ong-term clinical follow-up. Complete clinical follow-up
as obtained in 98.2% of the cases. Mean follow-up time
as 4.73  0.98 years (median of 5.01 years, interquartile
ange 4.04 to 5.11 months).
At the end of the follow-up period, 84.6% of the patients
ere free of any MACE. Cardiac death was observed in
.4% of the cohort, and only 6.6% of the individuals had
VR. Figure 2 shows the Kaplan-Meier event-free survival
urves for MACE, cardiac death, and TVR up to 7 years.
Table 4 details the DES thrombosis cases according to
he Academic Research Consortium definition. A total of
7 stent thromboses (2.6%) were observed in this series,
ncluding definite, probable, and possible cases. Among
hem, 17 cases (1.7%) were classified as definite/probable.
ine of these cases (0.9%) occurred after the first year of the
ndex procedure (Fig. 3).
ultivariate analysis. Independent predictors of MACE
ere acute myocardial infarction as the initial clinical
resentation (hazard ratio [HR]: 1.57; 95% confidence
nterval [CI]: 1.04 to 2.38, p  0.033), treatment of lesion
n grafts (HR: 1.94; 95% CI: 1.41 to 2.67, p  0.001),
esidual stenosis (HR: 1.3; 95% CI: 1.1 to 1.5, p  0.034).
strong tendency toward treatment of multivessel disease
as also observed (HR: 1.3; 95% CI: 0.97 to 1.85, p 
Table 1. Baseline Clinical Demographics (n  1,010)
Age, yrs 63.7 11.6
Female sex 232 (23.0%)
Diabetes mellitus 274 (27.1%)
Hypertension 746 (73.9%)
Hyperlipidemia 590 (58.4%)
Current smoker 313 (31.0%)
Previous MI 184 (18.2%)
Previous PCI 259 (25.5%)
Previous CABG 290 (28.7%)
Family history of CAD 498 (49.3%)
Obesity* 233 (23.9%)
Symptoms (clinical presentation)
Silent ischemia 281 (27.9%)
Stable angina 349 (34.5%)
Unstable angina/non–ST-segment elevation MI 257 (25.4%)
ST-segment elevation MI 123 (12.2%)
*Body mass index30 kg/m2.
CABG coronary arterybypass graft surgery; CAD coronary artery disease; MImyocardial
infarction; PCI percutaneous coronary intervention..07).Independent predictors of cardiac death were age 75
ears (HR: 2.27; 95% CI: 1.3 to 3.97, p 0.004), treatment
f lesions in grafts (HR: 2.54; 95% CI: 1.49 to 4.33, p 
.001), and history of peripheral disease (HR: 2.54; 95% CI:
.49 to 4.33, p  0.001).
Independent predictors of TVR were treatment of lesions
n grafts (HR: 1.59; 95% CI: 1.06 to 2.93, p  0.001) and
reatment of multivessel disease (HR: 2.72; 95% CI: 1.29 to
.77, p  0.009).
Finally, independent predictors of overall stent thrombo-
is were PCI in the setting of acute myocardial infarction
HR: 3.22; 95% CI: 1.40 to 7.41, p  0.006), DES
verlapping (HR: 3.02; 95% CI: 1.27 to 7.19, p  0.012),
reatment of multivessel disease (HR: 2.41; 95% CI: 1.04 to
.81, p  0.018), presence of moderate-to-severe calcifica-
ion at lesion site (HR: 2.21; 95% CI: 1.20 to 4.07, p 
.01), and in-stent residual stenosis (HR: 1.02; 95% CI:
.02 to 1.07, p  0.001).
Table 2. Pre-Procedural Lesion Characteristics (n  1,010)
Number of disease vessels*
1 46.7%
2 30.4%
3 22.9%
Treated vessel
Native coronary 93.7%
LAD 40.4%
LCX 23.5%
RCA 28.7%
LM 1.1%
Grafts 6.3%
Venous 94.4%
Arterial 5.6%
Lesion class A/B1/B2/C† 4.7%/28.8%/38.6%/27.9%
TIMI ﬂow grade
0 1.4%
1 0.5%
2 1.0%
3 97.1%
Thrombus 3.0%
Moderate-to-severe calciﬁcation 25.0%
Ostial lesion 5.1%
Bifurcation‡ 3.0%
In-stent restenosis§ 4.3%
Left ventricular function
Normal-to-mild dysfunction 58.4%
Moderate-to-severe dysfunction 41.6%
n  1,294 lesions. *50% diameter stenosis in a major epicardial vessel; †according to the
American College of Cardiology/American Heart Association lesion classification; ‡50% diam-
eter stenosis in the main vessel and in a side branch 2.25 mm (by visual estimation); §81%
post-bare-metal stent; normal-to-mild dysfunction  ejection fraction 40%, moderate-to-
severe dysfunction ejection fraction40%.
LAD left anterior descending coronary artery; LCX left circumflex coronary artery; LM leftmain coronary artery; RCA right coronary artery; TIMI Thrombolysis InMyocardial Infarction.
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16iscussion
he outcomes of the DESIRE-Late Registry indicate the very
ong-term maintenance of the results of first-generation DES,
ith a relatively low incidence of MACE extending to 7 years
fter DES implantation. Despite continuous hazard of very
ate stent thrombosis, the occurrence of this adverse event
ight not be as frequent as speculated.
In the scenario of clinical controlled trials, Stone et al. (6),
n a meta-analysis with more than 5,000 patients from the
ivotal studies with first-generation DES had previously
emonstrated the long-term (up to 4 years) sustained
uperiority of Cypher and Taxus over BMS in reducing the
eed for repeated revascularization (7.8% and 10.1% vs.
3.1% and 20.0% for their bare-metal equivalents, p 0.05)
ithout significant differences with regard to death (6.7%
nd 6.1% with Cypher and Taxus vs. 5.3% and 6.6% with
heir control studies, p  NS), myocardial infarction (6.4%
nd 7.0% with Cypher and Taxus vs. 6.2% and 6.3% in the
Table 3. Procedural Data (n  1,010)
Heparin use 100%
Glycoprotein IIb/IIIa use 2.7%
Balloon dilation
Pre-stenting 41.0%
Post-stenting 43.7%
Stent implant
1 stent implanted (per patient) 38.1%
Number of stents per lesion 1.3
Number of stents per patient 1.4
Total stented length, mm 19.2 5.8
Type of drug-eluting stent deployed
Cypher 81.0%
Taxus 19.0%
Nominal stent diameter, mm 2.87 0.38
Pre-procedural QCA
Lesion length, mm 16.4 8.2
RVD, mm 2.76 0.47
MLD, mm 1.04 1.74
DS, % 67.0 12.4
Post-procedural QCA
MLD, mm 2.85 1.0
DS, % 4.7 3.6
Acute gain, mm 1.81 0.9
Stent/lesion length ratio 1.2
Maximum pressure, atm 15.1 3.9
Balloon-artery ratio 1.12
Intraprocedural stent thrombosis 0%
Acute stent thrombosis 0%
Angiographic success 99.0%
Procedure success 98.3%
n 1,294 lesions.
DS  diameter stenosis; MLD  minimum lumen diameter; QCA  quantitative coronary
angiography; RVD reference vessel diameter.ontrol cohort, p  NS), and stent thrombosis (1.2% andFigure 2. Survival-Free Curves
Kaplan-Meier survival-free curves of major adverse clinical events (MACE)
(cardiac death, nonfatal acute myocardial infarction, and need for repeat
revascularization) (A), cardiac death (B), and target vessel revascularization
(TVR) (C) curves: drug-eluting stents demonstrated a very efﬁcient and safe
long-term performance in this unselected cohort of patients. At the bot-
tom of each panel is the number of patients evaluated in each follow-up
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17.3% with Cypher and Taxus vs. 0.6% and 0.9% with their
are-metal equivalents, p  NS).
The previous longest available nonselected series of pa-
ients treated with DES also confirmed the prolonged
enefits of these novel devices over BMS with respect to
eduction of repeated revascularization procedures. Daemen
t al. (7) published in 2006 the 3-year results of the
ESEARCH (Rapamycin-Eluting Stent Evaluated at Rot-
erdam Cardiology Hospital) registry comparing Cypher to
historical cohort of patients treated with BMS and
ollowed for an equivalent period. In their report with500
atients treated with DES, this novel device presented a
nal cumulative incidence of MACE, death, and TVR of
8.9%, 8.7%, and 9.4%. Next, Daemen et al. (8) presented
he 3-year results of the combined experience with DES in
ern and Rotterdam. In their analysis of 8,146 patients
reated with first-generation DES, the cumulative incidence
f death/myocardial infarction and definite stent thrombosis
ere 13.7% and 2.9%, respectively. More recently,
enaweser et al. (9) presented the 4-year follow-up of that
ame cohort, showing a cumulative incidence of death,
yocardial infarction, and stent thrombosis of 10.6%, 4.6%,
nd 3.3%, with a steady increment in stent thrombosis of
.53% per year. Also in 2009, Pfisterer et al. (10) published
he 3-year results of the BASKET (BAsel Stent KostenEf-
ektivitäts Trial), with 826 unselected patients randomized
n a 2:1 fashion to DES versus BMS. Their study showed a
ontinuous superiority of DES over BMS in reducing target
esion revascularization, mostly noticeable in small stents
10.7% vs. 19.8%, p  0.03) with equivalent rates of
eath/myocardial infarction between the cohorts. Of notice,
hey observed an increase in the combination death/
yocardial infarction after the first 6 months of the baseline
rocedure among patients receiving DES, mainly due to
ncreased late death/myocardial infarction in patients with
arge stents (9.7% vs. 3.1%, p  0.006).
Compared with these studies, our current analysis shows
better efficacy and safety profile of DES, with lower rates
f MACE, TVR, and definite/probable stent thrombosis
espite our having the longest follow-up time. Some pos-
ible explanations can be pointed out to enlighten our
Table 4. Classification of All DES Thrombosis Cases in the DESIRE-Late
Registry According to the ARC Definition (27 of 1,010 Patients)
Definite Probable Possible Total
Acute 0 0 0 0
Subacute 4 0 0 4 (0.4%)
Late 4 0 6 10 (0.9%)
Very late 9 0 4 13 (1.3%)
Total 17 (1.7%) 0 10 (0.9%) 27 (2.6%)
ARCAcademic Research Consortium; DES drug-eluting stent(s); DESIRE-LateDrug-Eluting
Stents In the REal world-Late registry.esults: 1) optimization of stent deployment, using onlineCA to guide all the procedures, and, whenever necessary,
areful post-dilation with shorter noncompliant balloon
lways avoiding injuring outside the limits of the stent;
nd 2) conscious selection of patients and lesions that would
etter benefit from coronary artery bypass grafting versus
CI. For example, in our institution most unprotected left
ain lesions involving the origin of the left anterior de-
cending coronary artery/left circumflex artery, selected
ifurcations involving big branches (2.5 mm in diameter)
nd other territories, diabetic patients with triple-vessel
iffuse disease in small diameter coronary vessels, and so on
re still preferably referred to cardiac surgery.
Finally, it is worthwhile to describe our population with
tent thrombosis. Our incidence of this adverse event is
bout 0.13% per year after the first year of the DES
eployment. In this cohort, death was the result of stent
hrombosis in 9 cases (33% of all stent thrombosis). Also
mportant to notice, nonadherence to dual antiplatelet
herapy was not an independent predictor of thrombosis in
he present study. Only 4 cases (15%) of stent thrombosis
all subacute) were clearly related to premature discontinu-
tion of the antiplatelet medication. In our opinion, the fact
hat a vast majority of patients were prescribed dual anti-
latelet therapy for 6 months, in addition to the strong
mphasis dispensed to the importance of compliance to the
rescribed medication at the time of the hospital discharge
s well as at every follow-up visit/telephone contact, may
ave played a fundamental role in the aspirin/thienopiridine
dherence.
tudy limitations. This is not a randomized study. The
onexistence of a control group treated with BMS precludes
ny comparison between these 2 technologies. The current
esults reflect the experience of a single institution with
rst-generation DES. The unbalanced use of Cypher and
axus prevents comparisons between these 2 DES. Finally,
Figure 3. Stent Thrombosis Incidence
Cumulative incidence of deﬁnite/probable stent thrombosis (ARC deﬁnition)
in the DESIRE (Drug-Eluting Stents In the REal world)-Late registry. Notice
that 0.9% of the cases happened after the ﬁrst year of the index procedure.
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Very Late DES Outcomes
18he relatively low number of stent thrombosis over-fitted the
ultivariate model built for that event, which may reduce
he strength of the findings regarding independent predic-
ors of that event.
onclusions
he deployment of DES in complex, real-world patients
esulted in excellent long-term results sustained at very long
erm follow-up, with low rates of MACE and stent throm-
osis. Nevertheless, stent thrombosis still occurs very long
fter the index procedure, but at a low annual rate.
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